A multicenter, phase I, pharmacokinetic study of osimertinib in cancer patients with normal renal function or severe renal impairment

Osimertinib is a third‐generation, irreversible, oral epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitor (TKI) that potently and selectively inhibits both EGFR‐TKI sensitizing and EGFR T790M and has demonstrated efficacy in non‐small cell lung cancer (NSCLC) central nervous system met...

Descripción completa

Detalles Bibliográficos
Autores principales: Vishwanathan, Karthick, Sanchez‐Simon, Inmaculada, Keam, Bhumsuk, Penel, Nicolas, de Miguel‐Luken, Maria, Weilert, Doris, Mills, Andrew, Marotti, Marcelo, Johnson, Martin, Ravaud, Alain
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307240/
https://www.ncbi.nlm.nih.gov/pubmed/32567817
http://dx.doi.org/10.1002/prp2.613

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7307240/
https://www.ncbi.nlm.nih.gov/pubmed/32567817
http://dx.doi.org/10.1002/prp2.613

Ejemplares similares